title: Influence of erythropoietin-stimulating agent treatment on glycated hemoglobin values in diabetic patients with chronic kidney disease.
authors.forename: Tomonari
authors.initials: T
authors.lastname: Okada
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Nakao
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Yume
authors.initials: Y
authors.lastname: Nagaoka
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Wada
mesh_terms: D000368:Aged; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism*; D017127:Glycation End Products, Advanced; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012709:Serum Albumin / Q000187:drug effects; D000093423:Glycated Serum Albumin
chemical_list: D004921:Erythropoietin; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D006397:Hematinics; D011994:Recombinant Proteins; D012709:Serum Albumin; D000093423:Glycated Serum Albumin